Cancer Research and Treatment

Original Articles

Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1–Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial: Dong Ki Lee, Choong-kun Lee, Hyo Song Kim, Sun Jin Sym, Dae Young Zang, Ki Hyang Kim, Joo Han Lim, Hae Su Kim, Kyung Hee Lee, Heon Yung Gee, Sun Young Rha, Hyunki Kim, Minkyu Jung; Received July 25, 2024 Accepted November 9, 2024 Published online November 12, 2024; DOI: https://doi.org/10.4143/crt.2024.705 [Epub ahead of print]

Abstract PDF Supplementary Material: Purpose
The nProfiler 1 Stomach Cancer Assay (nProfiler1), designed to predict responses to fluorouracil-based adjuvant chemotherapy, measures the expression of four gastric cancer target genes (GZMB, WARS, SFRP4, and CDX1). The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies: S-1 plus cisplatin (SP) and S-1 plus docetaxel (DS). This study aimed to validate the nProfiler1 assay using a distinct cohort from the POST trial.
Materials and Methods
The nProfiler1 assay stratifies patients into three groups (low-risk, intermediate-risk, and high-risk) using the prognostic single-patient classifier and two groups (chemotherapy-benefit and no-benefit) using the predictive single-patient classifier. The nProfiler1 assay was applied to formalin-fixed paraffin-embedded slides obtained from the POST trial. Disease-free survival (DFS) and overall survival (OS), including 5-year survival rates, were calculated for the enrolled patients.
Results
Of the 153 patients in the POST trial, 118 were included in the post-hoc analysis. With a median follow-up of 57.9 months, no significant difference in DFS or OS was observed between the SP and DS groups. The prognostic single-patient classifier predicted the OS in the SP group (p=0.043) but not in the DS group (p=0.594). The chemotherapy-benefit group exhibited numerically longer DFS than the no-benefit group in the SP and DS groups.
Conclusion
The nProfiler1 assay offers valuable insights into the prognosis and efficacy of adjuvant chemotherapy based on fluorouracil plus platinum doublet regimens but not docetaxel-containing regimens. Further validation with larger patient cohorts and different regimens is warranted.

532 View
73 Download

Gastrointestinal cancer

A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10): Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi; Cancer Res Treat. 2023;55(4):1250-1260. Published online May 25, 2023; DOI: https://doi.org/10.4143/crt.2023.333

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.
Materials and Methods
Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy.
Results
After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%.
Conclusion
Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.

Citations

Citations to this article as recorded by

A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort
Ziming Zhao, Erxun Dai, Bao Jin, Ping Deng, Zulihaer Salehebieke, Bin Han, Rongfan Wu, Zhaowu Yu, Jun Ren
Clinical and Translational Oncology.2024; 27(1): 135. CrossRef

3,874 View
302 Download
1 Web of Science
1 Crossref

Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea: Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An; Cancer Res Treat. 2020;52(1):277-283. Published online July 12, 2019; DOI: https://doi.org/10.4143/crt.2019.292

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.

Citations

Citations to this article as recorded by

Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
The Oncologist.2025;[Epub] CrossRef
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
Zesi Liu, Chunli Jing, Fandou Kong
Journal of Ovarian Research.2024;[Epub] CrossRef
SOX17 expression in ovarian clear cell carcinoma
Daichi Kodama, Motoki Takenaka, Chiemi Saigo, Masako Azuma, Yuki Hanamatsu, Masanori Isobe, Tamotsu Takeuchi
Journal of Ovarian Research.2024;[Epub] CrossRef
Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery
Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li
Clinical and Experimental Obstetrics & Gynecology.2024;[Epub] CrossRef
Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery
Li Shuqing, Zhu Zhiling
Cancer Medicine.2023; 12(6): 6668. CrossRef
Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis
Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani
Current Medical Research and Opinion.2023; 39(6): 901. CrossRef
The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
Yuan Zhuang, Hua Yang
Cancer Control.2023;[Epub] CrossRef
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
Satoe Fujiwara
Japanese Journal of Clinical Oncology.2023; 53(8): 664. CrossRef
Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee
Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients
Yang Gao, Wei Ding, Pengpeng Qu
Clinical and Experimental Obstetrics & Gynecology.2023;[Epub] CrossRef
A clearer view on ovarian clear cell carcinoma
Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys
Acta Clinica Belgica.2022; 77(4): 792. CrossRef
Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study
Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh
Archives of Gynecology and Obstetrics.2022; 305(5): 1279. CrossRef
Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis
Peng Chen, Chi-Yuan Zhang
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report
Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia
Medicine.2022; 101(37): e30666. CrossRef
Clear cell carcinoma of the ovary: a clinical and molecular perspective
Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington
International Journal of Gynecological Cancer.2021; 31(4): 605. CrossRef
Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou
BMC Cancer.2021;[Epub] CrossRef
The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable
Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN
Journal of Surgery and Medicine.2021; 5(8): 1. CrossRef
Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma
Qian Chen, Shu Wang, Jing-He Lang
Journal of Ovarian Research.2020;[Epub] CrossRef

9,172 View
422 Download
23 Web of Science
18 Crossref

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial: Choong-kun Lee, Minkyu Jung, Hyo Song Kim, Inkyung Jung, Dong Bok Shin, Seok Yun Kang, Dae Young Zang, Ki Hyang Kim, Moon Hee Lee, Bong-Seog Kim, Kyung Hee Lee, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2019;51(1):1-11. Published online February 5, 2018; DOI: https://doi.org/10.4143/crt.2018.028

Abstract PDF Supplementary Material PubReader ePub

Purpose
We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients.
Materials and Methods
Stage III gastric cancer patients who had received curative gastrectomy with D2 lymphadenectomy were randomized into equal groups to receive adjuvant chemotherapy of eight cycles of DS (S-1 70 mg/m² /day on days 1-14 plus docetaxel 35 mg/m² on days 1 and 8) every 3 weeks or SP (S-1 70 mg/m² /day on days 1-14 plus cisplatin 60 mg/m² on day 1) every 3 weeks. The primary endpoint was 3-year disease-free survival (DFS) rate.
Results
Between November 2010 and July 2013, 153 patients (75 patients to DS and 78 patients to SP) were enrolled from 8 institutions in Korea. After the capecitabine plus oxaliplatin was approved based on the CLASSIC study, itwas decided to close the study early. With a median follow-up duration of 56.9 months, the 3-year DFS rate between two groups was not significantly different (49.14% in DS group vs. 52.5% in SP group). The most common grade 3-4 adverse event was neutropenia (42.7% in DS and 38.5% in SP, p=0.351). SP group had more grade 3-4 anemia (1.3% vs. 11.5%, p=0.037), whereas grade 3-4 hand-foot syndrome (4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common in DS group. Fifty-one patients (68%) in DS group and 52 (66.7%) in SP group finished planned treatment.
Conclusion
Our findings suggest that SP or DS is an effective and tolerable option for patients with curatively resected stage III gastric cancer.

Citations

Citations to this article as recorded by

Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
Hui-Fen Lv, Li-Feng Qin, Rui-Zhi Ran, Xue-Ping Jiang, Fang-Yu Zhao, Bo Li
Frontiers in Pharmacology.2024;[Epub] CrossRef
A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer
Lili Liu, Li Sun, Ning Zhang, Cheng-gong Liao, Haichuan Su, Jie Min, Yang Song, Xue Yang, Xiaofeng Huang, Dongxu Chen, Yu Chen, Hong-wei Zhang, Helong Zhang
International Journal of Hyperthermia.2022; 39(1): 239. CrossRef
Comment on “post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial”
Qiang Hu, Yuanshui Sun
Clinical Nutrition.2021; 40(3): 1438. CrossRef
THE ROLE OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
A. A. Bobryshev, M. M. Davudov, M. N. Narimanov, S. B. Polycarpova, V. Y. Kirsanov, V. N. Blindar
Siberian journal of oncology.2021; 20(1): 133. CrossRef
Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
Surgical Oncology.2021; 38: 101599. CrossRef
Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
Chih-Chieh Yen, Yan-Shen Shan, Ying-Jui Chao, Ting-Kai Liao, I-Shu Chen, Hsuan-Yi Huang, I-Ting Liu, Chia-Jui Yen
BMC Cancer.2021;[Epub] CrossRef
Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?
Ina Valeria Zurlo, Michele Basso, Antonia Strippoli, Maria Alessandra Calegari, Armando Orlandi, Alessandra Cassano, Mariantonietta Di Salvatore, Giovanna Garufi, Emilio Bria, Giampaolo Tortora, Carlo Barone, Carmelo Pozzo
Cancers.2020; 12(7): 1749. CrossRef
A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer
Long Ge, Liangying Hou, Qingxia Yang, Yiting Wu, Xiue Shi, Jiang Li, Kehu Yang
Medicine.2019; 98(7): e14478. CrossRef
Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Cancers.2019; 11(4): 530. CrossRef
COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Frontiers in Oncology.2019;[Epub] CrossRef
Cutting-edge evidence of adjuvant treatments for gastric cancer
Dai Shimizu, Mitsuro Kanda, Yasuhiro Kodera, Junichi Sakamoto
Expert Review of Gastroenterology & Hepatology.2018; 12(11): 1109. CrossRef

13,287 View
591 Download
22 Web of Science
11 Crossref

Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08: Ki Hyang Kim, Joo Hoon Kim, Ji Young Lee, Hyo Song Kim, Su Jin Heo, Ji Hyung Kim, Ho Young Kim, Sun Young Rha; Cancer Res Treat. 2016;48(4):1286-1292. Published online February 12, 2016; DOI: https://doi.org/10.4143/crt.2016.018

Abstract PDF PubReader ePub

Purpose
We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. Materials and Methods Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment.
Results
Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m2. The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level. Conclusion Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.

Citations

Citations to this article as recorded by

Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis
Manuel Eros Rodríguez-Fuentes, Mario Pérez-Sayáns, Carmen Martín Carreras-Presas, Xabier Marichalar-Mendia, Leticia Bagán-Debón, Rafael López-López
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2023; 135(3): 385. CrossRef
Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function
Łukasz Mielczarek, Anna Brodziak, Paweł Sobczuk, Maciej Kawecki, Agnieszka Cudnoch-Jędrzejewska, Anna M. Czarnecka
Cancer Chemotherapy and Pharmacology.2021; 87(6): 723. CrossRef
Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study
Cristina Masini, Maria Giuseppa Vitale, Marco Maruzzo, Giuseppe Procopio, Ugo de Giorgi, Sebastiano Buti, Sabrina Rossetti, Roberto Iacovelli, Francesco Atzori, Laura Cosmai, Francesca Vignani, Giuseppe Prati, Sarah Scagliarini, Annalisa Guida, Annalisa B
Clinical Genitourinary Cancer.2019; 17(1): e150. CrossRef
Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials
Ravi K. Paluri, Guru Sonpavde, Charity Morgan, Jacob Rojymon, Anastasia Hartzes Mar, Radhika Gangaraju
Oncology Reviews.2019;[Epub] CrossRef

10,434 View
144 Download
3 Web of Science
4 Crossref

Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites: Joo Hoon Kim, Sun Young Rha, Chan Kim, Gun Min Kim, Sang Hyun Yoon, Ki Hyang Kim, Min Jae Kim, Joong Bae Ahn, Hyun Cheol Chung, Jae Kyung Roh, Hyo Song Kim; Cancer Res Treat. 2010;42(4):217-224. Published online December 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.4.217

Abstract PDF PubReader ePub

Purpose

We investigated the clinicopathologic information of patients with gastric cancer with multiple primary cancers (GC-MPC) of three or more sites.

Materials and Methods

Between 1995 and 2009, 105,908 patients were diagnosed with malignancy at Severance Hospital, Yonsei University Health System. Of these, 113 (0.1%) patients with MPC of three or more sites were registered, and 41 (36.3%) of these were GC-MPC. We retrospectively reviewed the clinical data and overall survival using the medical records of these 41 GC-MPC patients. We defined synchronous cancers as those occurring within 6 months of the first primary cancer, while metachronous cancers were defined as those occurring more than 6 months later.

Results

Patients with metachronous GC-MPC were more likely to be female (p=0.003) and young than patients with synchronous GC-MPC (p=0.013). The most common cancer sites for metachronous GC-MPC patients were the colorectum, thyroid, lung, kidney and breast, while those for synchronous GC-MPC were the head and neck, esophagus, lung, and kidney. Metachronous GC-MPC demonstrated significantly better overall survival than synchronous GC-MPC, with median overall survival durations of 4.7 and 14.8 years, respectively, and 10-year overall survival rates of 48.2% and 80.7%, respectively (p<0.001).

Conclusion

Multiplicity of primary malignancies itself does not seem to indicate a poor prognosis. The early detection of additional primary malignancies will enable proper management with curative intent.

Citations

Citations to this article as recorded by

Metachronous or Synchronous Presentation of Acute Myeloid Leukemia and Lung Cancer: A Single Center Experience
Başak Ünver Koluman, Atike Gökçen Demiray, Gulsum Akgun Cagliyan, Sibel Hacıoğlu, Nil Güler, Taner Durak, Yeliz Karakaya, Ferda Bir
Akdeniz Medical Journal.2024;[Epub] CrossRef
A Disguising Fast-Growing Metachronous Melanoma and COVID-19
Alina Avram, Lucian G Scurtu, Mariana Costache, Olga Simionescu
Cureus.2023;[Epub] CrossRef
Solitary solutions to a metastasis model represented by two systems of coupled Riccati equations
I. Timofejeva, T. Telksnys, Z. Navickas, R. Marcinkevicius, R. Mickevicius, M. Ragulskis
Journal of King Saud University - Science.2023; 35(5): 102682. CrossRef
Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report
Oliver Oey, Siaw Sze Tiong, Sze Ling Wong, Suresh Navadgi, Yasir Khan
Folia Medica.2023; 65(4): 693. CrossRef
Features of synchronous and metachronous dual primary gastric and colorectal cancer
Yi-Jia Lin, Hua-Xian Chen, Feng-Xiang Zhang, Xian-Sheng Hu, Hai-Juan Huang, Jian-Hua Lu, Ye-Zi Cheng, Jun-Sheng Peng, Lei Lian
World Journal of Gastrointestinal Oncology.2023; 15(11): 1864. CrossRef
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
Tiuri E. Kroese, Richard van Hillegersberg, Sebastian Schoppmann, Pieter R.A.J. Deseyne, Philippe Nafteux, Radka Obermannova, Marianne Nordsmark, Per Pfeiffer, Maria A. Hawkins, Elizabeth Smyth, Sheraz Markar, George B. Hanna, Edward Cheong, Asif Chaudry,
European Journal of Cancer.2022; 164: 18. CrossRef
Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study
Tiuri E. Kroese, Nikita K.N. Jorritsma, Hanneke W.M. van Laarhoven, Rob H.A. Verhoeven, Stella Mook, Nadia Haj Mohammad, Jelle P. Ruurda, Peter S.N. van Rossum, Richard van Hillegersberg
Clinical and Translational Radiation Oncology.2022; 37: 109. CrossRef
Simultaneous triple primary malignancies, including bladder cancer, lymphoma, and lung cancer, in an elderly male: A case report
Risheng Huang, Zhijia Li, Shanshan Weng, Shenghao Wu
Open Life Sciences.2022; 17(1): 1263. CrossRef
A Case Report of Mesothelioma Response to Endocrine Therapy in Synchronous Breast Cancer and Pleural Epithelioid Mesothelioma: A Double Exemestane Effect
Marta Pina, Rute Fernandes, Diogo Fonseca, Cristina Oliveira, Ana Rodrigues
Cureus.2022;[Epub] CrossRef
Management of patients with synchronous head-and-neck and lung cancers
Nicolas Paleiron, Radj Gervais, Gaelle Rousseau-Bussac, Laurence Bigay Game, Anne Marie Chiappa, Regine Lamy, Florian Guisier, Hervé Le Caer, Gilles Robinet, Acya Bizieux, Christos Chouaïd
Journal of Cancer Research and Therapeutics.2022; 18(Suppl 2): S160. CrossRef
Multiple primary malignancies involving lung cancer: a single-center experience
Luigi Ventura, Paolo Carbognani, Letizia Gnetti, Maurizio Rossi, Marcello Tiseo, Enrico Maria Silini, Nicola Sverzellati, Mario Silva, Marcello Succi, Cesare Braggio, Sara Cattadori, Giovanni Bocchialini, Valeria Balestra, Michele Rusca, Luca Ampollini
Tumori Journal.2021; 107(3): 196. CrossRef
A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma
Matthew I Ebia, Stephen Capone, Charité Ricker, Jacob S Thomas, Varsha Tulpule, Irene Kang, Anishka D'Souza, David R Freyer, Kimberly Miller, Gino K In
Cureus.2021;[Epub] CrossRef
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy
Ali Khalifa, Arkady Broder
Cureus.2021;[Epub] CrossRef
Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor
Xiaolong Hu, Hongqi Li, Xiaoli Kang, Xuan Wang, Haifeng Pang, Chen Liu, Jianchun Zhang, Yingjie Wang
Cancer Management and Research.2021; Volume 13: 9247. CrossRef
Synergistic Effect of Lymphatic Invasion and Venous Invasion on the Risk of Lymph Node Metastasis in Patients with Non-Curative Endoscopic Resection of Early Gastric Cancer
Hye Jin Kang, Hyunsoo Chung, Sang Gyun Kim, Jung Kim, Jue Lie Kim, Eunwoo Lee, Hyun Chae Jung
Journal of Gastrointestinal Surgery.2020; 24(7): 1499. CrossRef
Clear cell renal carcinoma synchronous with dedifferentiated liposarcoma: a case report and review of the literature
Estefania Beltran, Juan Esteban Garcia-Robledo, Lisa X. Rodríguez-Rojas, Martin Rengifo, Bladimir Perez, Harry Pachajoa, Angela R. Zambrano
Journal of Medical Case Reports.2020;[Epub] CrossRef
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, Laurence Collette, Andre Dekker, Nandita M deSouza, Anne-Marie C Dingemans, Beatrice Fournier, Coen Hurkmans, Frédéric E Lecouvet, Icro Meattini, Alejandra Méndez Romero, Umberto Ricardi, Nicola S
The Lancet Oncology.2020; 21(1): e18. CrossRef
Rare heterochronous liver and pancreatic multiple primary cancers: a case report and literature review
Wangjun Zhang, Fan Xiao, Jie Li, Xiaoyu Guo, Zhitao Lin, Zijian Huang, Ning Mao, Bei Sun, Gang Wang
Zeitschrift für Gastroenterologie.2020; 58(11): 1094. CrossRef
Gastric carcinoma and renal cell carcinoma as an atypical presentation of multiple primary malignancies: a case report and review of the literature
J. A. Martín-Pérez, C. Torres-Silva, R. Tenorio-Arguelles, D. A. García-Corona, S. Silva-González, J. A. Dominguez-Rodriguez, I. De Alba-Cruz, J. F. Nagore-Ancona, J. A. González-Luna, K. A. López-Bochm
Journal of Medical Case Reports.2020;[Epub] CrossRef
Helicobacter pylori Eradication for Metachronous Gastric Cancer: An Unsuitable Methodology Impeding Broader Clinical Usage
Alexios-Fotios A. Mentis, Efthimios Dardiotis
Frontiers in Oncology.2019;[Epub] CrossRef
A case report of cholangiocarcinoma combined with moderately differentiated gastric adenocarcinoma
Yan-Hui Yang, Qing Deng, Tian-Bao Yang, Yang Gui, Yu-xiang Zhang, Jiang-Bo Liu, Qian Deng, Wei-Feng Liu, Jun-Jun Sun
Medicine.2019; 98(30): e16332. CrossRef
Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries
Asta Agasarova, Clare Harnett, Niall Mulligan, Muhammad Shakeel Majeed, Alberto Caimo, Gianluca Tamagno
International Journal of Endocrinology.2018; 2018: 1. CrossRef
Clinicopathologic characteristics and survival rate in patients with synchronous or metachronous double primary colorectal and gastric cancer
Ji-Hyeon Park, Jeong-Heum Baek, Jun-Young Yang, Won-Suk Lee, Woon-Kee Lee
Korean Journal of Clinical Oncology.2018; 14(2): 83. CrossRef
Synchronous primary of periampullary and lung cancer: A case report and review of literature
Vikas Talreja, Vanita Noronha, Amit Joshi, Vijay Patil, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2018; 1(2): 173. CrossRef
Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report
Huijie Fan, Pei Lu, Li Xu, Yanru Qin, Jing Li
BMC Cancer.2017;[Epub] CrossRef
Multiple primary malignancies involving lung cancer
Feng Li, Wen-Zhao Zhong, Fei-Yu Niu, Ning Zhao, Jin-Ji Yang, Hong-Hong Yan, Yi-Long Wu
BMC Cancer.2015;[Epub] CrossRef
Limitations of PET and PET/CT in detecting upper gastrointestinal synchronous cancer in patients with head and neck carcinoma
Kenichiro Yabuki, Akira Kubota, Choichi Horiuchi, Takahide Taguchi, Goshi Nishimura, Masahiko Inamori
European Archives of Oto-Rhino-Laryngology.2013; 270(2): 727. CrossRef

12,486 View
98 Download
27 Crossref

Case Report

Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis: Sang Hyun Yoon, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha; Cancer Res Treat. 2010;42(3):180-184. Published online September 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.3.180

Abstract PDF PubReader ePub

The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.

Citations

Citations to this article as recorded by

Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review
Elodie Klajer, Louis Garnier, Morgan Goujon, Friederike Schlurmann-Constans, Benoite Mery, Thierry Nguyen Tan Hon, Guillaume Mouillet, Fabien Calcagno, Antoine Thiery-Vuillemin
Seminars in Oncology.2020; 47(2-3): 103. CrossRef
Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality
Annalisa Guida, Laura Cosmai, Fabio Gelsomino, Cristina Masini, Roberto Sabbatini, Camillo Porta
EMJ Nephrology.2016; : 66. CrossRef
Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature
Daniele Minardi, Luigi Quaresima, Matteo Santoni, Maristella Bianconi, Mario Scartozzi, Stefano Cascinu, Giovanni Muzzonigro
Current Urology Reports.2015;[Epub] CrossRef
Feasibility, Efficacy and Safety of Tyrosine Kinase Inhibitor Treatment in Hemodialyzed Patients with Renal Cell Cancer: 10 Years of Experience
Anna M Czarnecka, Maciej Kawecki, Fei Lian, Jan Korniluk, Cezary Szczylik
Future Oncology.2015; 11(16): 2267. CrossRef
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency
Ki Hyang Kim, Ho Young Kim, Hye Ryun Kim, Jong-Mu Sun, Ho Yeong Lim, Hyo Jin Lee, Suee Lee, Woo Kyun Bae, Sun Young Rha
European Journal of Cancer.2014; 50(4): 746. CrossRef
Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran
Korean Journal of Urology.2014; 55(1): 74. CrossRef
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
Ahmed Alasker, Malek Meskawi, Maxine Sun, Salima Ismail, Nawar Hanna, Jens Hansen, Zhe Tian, Marco Bianchi, Paul Perrotte, Pierre I. Karakiewicz
Cancer Treatment Reviews.2013; 39(4): 388. CrossRef
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey
Cristina Masini, Roberto Sabbatini, Camillo Porta, Giuseppe Procopio, Giuseppe Di Lorenzo, Azzurra Onofri, Sebastiano Buti, Roberto Iacovelli, Roberta Invernizzi, Luca Moscetti, Maria Giuseppina Aste, Maria Pagano, Federica Grosso, Anna Lucia Manenti, Cin
BJU International.2012; 110(5): 692. CrossRef

10,308 View
67 Download
8 Crossref

First
Prev
Page of 1
Next
Last

Search